Whole-Genome Sequencing for Resistance Prediction and Transmission Analysis of Mycobacterium tuberculosis Complex Strains from Namibia

Claassens, Mareli; Dreyer, Viola; Nepolo, Emmanuel; Mokomele, Q; Rooyen, Gerhard van; Ruswa, Nunurai; Günther, Gunar; Niemann, Stefan

doi:10.1128/spectrum.01586-22

Cited by 2 publications

(1 citation statement)

References 33 publications

(40 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Only primary quantitative studies were selected from the search output. The title of the study, year of study, study setting, study design, MDR-TB confirmed number of cases, MDR-TB/HIV co-infection proportion, and the outcome explored were characteristics retrieved from the studies (Table 1 ) [ 9 – 13 , 14 ▪▪ , 15 – 21 , 22 ▪▪ , 23 , 24 ▪▪ , 25 – 29 , 30 ▪ , 31 ▪ , 32 – 36 , 37 ▪▪ , 38 – 48 , 49 ▪▪ , 50 ▪ ].…”

Section: Search Methodsmentioning

confidence: 99%

Multidrug-resistant tuberculosis: latest opinions on epidemiology, rapid diagnosis and management

Nyasulu,

Doumbia,

Ngah

et al. 2024

Current Opinion in Pulmonary Medicine

View full text Add to dashboard Cite

Purpose of review This review addresses the escalating global challenge of multidrug-resistant tuberculosis (MDR-TB) in Sub-Saharan Africa, with a focus on its complex comorbidity with HIV/AIDS. Emphasizing the urgency of the issue, the review aims to shed light on the unique healthcare landscape shaped by the convergence of high prevalence rates and intersecting complexities with HIV/AIDS in the region. Recent findings A notable increase in MDR-TB cases across Sub-Saharan Africa is attributed to challenges in timely diagnoses, treatment initiation, and patient treatment defaulting. The literature underscores the critical need for proactive measures to address diagnostic and treatment gaps associated with MDR-TB, particularly concerning its comorbidity with HIV/AIDS. Summary To effectively manage MDR-TB and its co-morbidity with HIV/AIDS, proactive screening programs are imperative. The review highlights the necessity of active follow-up strategies to ensure treatment adherence and reduce default rates, offering evidence-based insights for improved disease management in the region.

show abstract

Section: Search Methodsmentioning

confidence: 99%

Multidrug-resistant tuberculosis: latest opinions on epidemiology, rapid diagnosis and management

Nyasulu,

Doumbia,

Ngah

et al. 2024

Current Opinion in Pulmonary Medicine

View full text Add to dashboard Cite

show abstract

Molecular determinants of multidrug-resistant tuberculosis in Sierra Leone

Blankson,

Kamara,

Barilar

et al. 2024

Microbiol Spectr

View full text Add to dashboard Cite

Multidrug-resistant tuberculosis (MDR-TB) management has become a serious global health challenge. Understanding its epidemic determinants on the regional level is crucial for developing effective control measures. We used whole genome sequencing data of 238 of Mycobacterium tuberculosis complex (MTBC) strains to determine drug resistance profiles, phylogeny, and transmission dynamics of MDR/rifampicin-resistant (RR) MTBC strains from Sierra Leone. Forty-two strains were classified as RR, 196 as MDR, 5 were resistant to bedaquiline (BDQ) and clofazimine (CFZ), but none was found to be resistant to fluoroquinolones. Sixty-one (26%) strains were resistant to all first-line drugs, three of which had additional resistance to BDQ/CFZ. The strains were classified into six major MTBC lineages (L), with strains of L4 being the most prevalent, 62% ( n = 147), followed by L6 ( Mycobacterium africanum ) strains, (21%, n = 50). The overall clustering rate (using ≤d12 single-nucleotide polymorphism threshold) was 44%, stratified into 31 clusters ranging from 2 to 16 strains. The largest cluster ( n = 16) was formed by sublineage 2.2.1 Beijing Ancestral 3 strains, which developed MDR several times. Meanwhile, 10 of the L6 strains had a primary MDR transmission. We observed a high diversity of drug resistance mutations, including borderline resistance mutations to isoniazid and rifampicin, and mutations were not detected by commercial assays. In conclusion, one in five strains investigated was resistant to all first-line drugs, three of which had evidence of BDQ/CFZ resistance. Implementation of interventions such as rapid diagnostics that prevent further resistance development and stop MDR-TB transmission chains in the country is urgently needed. IMPORTANCE A substantial proportion of MDR-TB strains in Sierra Leone were resistant against all first line drugs; however this makes the all-oral-six-month BPaLM regimen or other 6-9 months all oral regimens still viable, mainly because there was no FQ resistance.Resistance to BDQ was detected, as well as RR, due to mutations outside of the hotspot region. While the prevalence of those resistances was low, it is still cause for concern and needs to be closely monitored.

show abstract

Whole-Genome Sequencing for Resistance Prediction and Transmission Analysis of Mycobacterium tuberculosis Complex Strains from Namibia

Cited by 2 publications

References 33 publications

Multidrug-resistant tuberculosis: latest opinions on epidemiology, rapid diagnosis and management

Multidrug-resistant tuberculosis: latest opinions on epidemiology, rapid diagnosis and management

Molecular determinants of multidrug-resistant tuberculosis in Sierra Leone

Contact Info

Product

Resources

About